Global Oligonucleotide Therapy-based Drug Supply, Demand and Key Producers, 2023-2029
The global Oligonucleotide Therapy-based Drug market size is expected to reach $ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
This report studies the global Oligonucleotide Therapy-based Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oligonucleotide Therapy-based Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oligonucleotide Therapy-based Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oligonucleotide Therapy-based Drug total market, 2018-2029, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Oligonucleotide Therapy-based Drug total market, key domestic companies and share, (USD Million)
Global Oligonucleotide Therapy-based Drug revenue by player and market share 2018-2023, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Oligonucleotide Therapy-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oligonucleotide Therapy-based Drug market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oligonucleotide Therapy-based Drug Market, By Region:
1. How big is the global Oligonucleotide Therapy-based Drug market?
2. What is the demand of the global Oligonucleotide Therapy-based Drug market?
3. What is the year over year growth of the global Oligonucleotide Therapy-based Drug market?
4. What is the total value of the global Oligonucleotide Therapy-based Drug market?
5. Who are the major players in the global Oligonucleotide Therapy-based Drug market?
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
This report studies the global Oligonucleotide Therapy-based Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oligonucleotide Therapy-based Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oligonucleotide Therapy-based Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oligonucleotide Therapy-based Drug total market, 2018-2029, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Oligonucleotide Therapy-based Drug total market, key domestic companies and share, (USD Million)
Global Oligonucleotide Therapy-based Drug revenue by player and market share 2018-2023, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Oligonucleotide Therapy-based Drug total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Oligonucleotide Therapy-based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oligonucleotide Therapy-based Drug market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oligonucleotide Therapy-based Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1. How big is the global Oligonucleotide Therapy-based Drug market?
2. What is the demand of the global Oligonucleotide Therapy-based Drug market?
3. What is the year over year growth of the global Oligonucleotide Therapy-based Drug market?
4. What is the total value of the global Oligonucleotide Therapy-based Drug market?
5. Who are the major players in the global Oligonucleotide Therapy-based Drug market?
1 SUPPLY SUMMARY
1.1 Oligonucleotide Therapy-based Drug Introduction
1.2 World Oligonucleotide Therapy-based Drug Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Oligonucleotide Therapy-based Drug Total Market by Region (by Headquarter Location)
1.3.1 World Oligonucleotide Therapy-based Drug Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.3 China Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.4 Europe Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.5 Japan Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.6 South Korea Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.7 ASEAN Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.8 India Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oligonucleotide Therapy-based Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oligonucleotide Therapy-based Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.2 World Oligonucleotide Therapy-based Drug Consumption Value by Region
2.2.1 World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023)
2.2.2 World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029)
2.3 United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.4 China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.5 Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.6 Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.7 South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.8 ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.9 India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
3 WORLD OLIGONUCLEOTIDE THERAPY-BASED DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oligonucleotide Therapy-based Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug in 2022
3.2.3 Global Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug in 2022
3.3 Oligonucleotide Therapy-based Drug Company Evaluation Quadrant
3.4 Oligonucleotide Therapy-based Drug Market: Overall Company Footprint Analysis
3.4.1 Oligonucleotide Therapy-based Drug Market: Region Footprint
3.4.2 Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
3.4.3 Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oligonucleotide Therapy-based Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oligonucleotide Therapy-based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Oligonucleotide Therapy-based Drug Consumption Value Comparison
4.2.1 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Oligonucleotide Therapy-based Drug Companies and Market Share, 2018-2023
4.3.1 United States Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
4.4 China Based Companies Oligonucleotide Therapy-based Drug Revenue and Market Share, 2018-2023
4.4.1 China Based Oligonucleotide Therapy-based Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
4.5 Rest of World Based Oligonucleotide Therapy-based Drug Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antisense Oligonucleotides (ASO)
5.2.2 siRNA
5.2.3 mRNA
5.3 Market Segment by Type
5.3.1 World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023)
5.3.2 World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029)
5.3.3 World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuromuscular Diseases
6.2.2 hATTR
6.2.3 COVID-19
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023)
6.3.2 World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029)
6.3.3 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Details
7.1.2 Sarepta Therapeutics Major Business
7.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sarepta Therapeutics Recent Developments/Updates
7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Details
7.2.2 Ionis Pharmaceuticals Major Business
7.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
7.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Ionis Pharmaceuticals Recent Developments/Updates
7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Alnylam
7.3.1 Alnylam Details
7.3.2 Alnylam Major Business
7.3.3 Alnylam Oligonucleotide Therapy-based Drug Product and Services
7.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Alnylam Recent Developments/Updates
7.3.6 Alnylam Competitive Strengths & Weaknesses
7.4 Biogen
7.4.1 Biogen Details
7.4.2 Biogen Major Business
7.4.3 Biogen Oligonucleotide Therapy-based Drug Product and Services
7.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Biogen Recent Developments/Updates
7.4.6 Biogen Competitive Strengths & Weaknesses
7.5 Nippon Shinyaku
7.5.1 Nippon Shinyaku Details
7.5.2 Nippon Shinyaku Major Business
7.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services
7.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Nippon Shinyaku Recent Developments/Updates
7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses
7.6 Sobi
7.6.1 Sobi Details
7.6.2 Sobi Major Business
7.6.3 Sobi Oligonucleotide Therapy-based Drug Product and Services
7.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Sobi Recent Developments/Updates
7.6.6 Sobi Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Oligonucleotide Therapy-based Drug Product and Services
7.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 BioNTech
7.8.1 BioNTech Details
7.8.2 BioNTech Major Business
7.8.3 BioNTech Oligonucleotide Therapy-based Drug Product and Services
7.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 BioNTech Recent Developments/Updates
7.8.6 BioNTech Competitive Strengths & Weaknesses
7.9 Pfizer
7.9.1 Pfizer Details
7.9.2 Pfizer Major Business
7.9.3 Pfizer Oligonucleotide Therapy-based Drug Product and Services
7.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Recent Developments/Updates
7.9.6 Pfizer Competitive Strengths & Weaknesses
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Details
7.10.2 Moderna Therapeutics Major Business
7.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Moderna Therapeutics Recent Developments/Updates
7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Details
7.11.2 Jazz Pharmaceuticals Major Business
7.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
7.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.12 CureVac
7.12.1 CureVac Details
7.12.2 CureVac Major Business
7.12.3 CureVac Oligonucleotide Therapy-based Drug Product and Services
7.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 CureVac Recent Developments/Updates
7.12.6 CureVac Competitive Strengths & Weaknesses
7.13 Regulus Therapeutics
7.13.1 Regulus Therapeutics Details
7.13.2 Regulus Therapeutics Major Business
7.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Regulus Therapeutics Recent Developments/Updates
7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses
7.14 ProQR
7.14.1 ProQR Details
7.14.2 ProQR Major Business
7.14.3 ProQR Oligonucleotide Therapy-based Drug Product and Services
7.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 ProQR Recent Developments/Updates
7.14.6 ProQR Competitive Strengths & Weaknesses
7.15 Secarna
7.15.1 Secarna Details
7.15.2 Secarna Major Business
7.15.3 Secarna Oligonucleotide Therapy-based Drug Product and Services
7.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Secarna Recent Developments/Updates
7.15.6 Secarna Competitive Strengths & Weaknesses
7.16 MiNA Therapeutics
7.16.1 MiNA Therapeutics Details
7.16.2 MiNA Therapeutics Major Business
7.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 MiNA Therapeutics Recent Developments/Updates
7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses
7.17 Sylentis
7.17.1 Sylentis Details
7.17.2 Sylentis Major Business
7.17.3 Sylentis Oligonucleotide Therapy-based Drug Product and Services
7.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sylentis Recent Developments/Updates
7.17.6 Sylentis Competitive Strengths & Weaknesses
7.18 Arrowhead
7.18.1 Arrowhead Details
7.18.2 Arrowhead Major Business
7.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product and Services
7.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Arrowhead Recent Developments/Updates
7.18.6 Arrowhead Competitive Strengths & Weaknesses
7.19 Silence Therapeutics
7.19.1 Silence Therapeutics Details
7.19.2 Silence Therapeutics Major Business
7.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Silence Therapeutics Recent Developments/Updates
7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
7.20 Dicerna
7.20.1 Dicerna Details
7.20.2 Dicerna Major Business
7.20.3 Dicerna Oligonucleotide Therapy-based Drug Product and Services
7.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Dicerna Recent Developments/Updates
7.20.6 Dicerna Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oligonucleotide Therapy-based Drug Industry Chain
8.2 Oligonucleotide Therapy-based Drug Upstream Analysis
8.3 Oligonucleotide Therapy-based Drug Midstream Analysis
8.4 Oligonucleotide Therapy-based Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Oligonucleotide Therapy-based Drug Introduction
1.2 World Oligonucleotide Therapy-based Drug Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Oligonucleotide Therapy-based Drug Total Market by Region (by Headquarter Location)
1.3.1 World Oligonucleotide Therapy-based Drug Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.3 China Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.4 Europe Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.5 Japan Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.6 South Korea Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.7 ASEAN Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.3.8 India Oligonucleotide Therapy-based Drug Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oligonucleotide Therapy-based Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Oligonucleotide Therapy-based Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.2 World Oligonucleotide Therapy-based Drug Consumption Value by Region
2.2.1 World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023)
2.2.2 World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029)
2.3 United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.4 China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.5 Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.6 Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.7 South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.8 ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
2.9 India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029)
3 WORLD OLIGONUCLEOTIDE THERAPY-BASED DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oligonucleotide Therapy-based Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug in 2022
3.2.3 Global Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug in 2022
3.3 Oligonucleotide Therapy-based Drug Company Evaluation Quadrant
3.4 Oligonucleotide Therapy-based Drug Market: Overall Company Footprint Analysis
3.4.1 Oligonucleotide Therapy-based Drug Market: Region Footprint
3.4.2 Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
3.4.3 Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oligonucleotide Therapy-based Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oligonucleotide Therapy-based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Oligonucleotide Therapy-based Drug Consumption Value Comparison
4.2.1 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Oligonucleotide Therapy-based Drug Companies and Market Share, 2018-2023
4.3.1 United States Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
4.4 China Based Companies Oligonucleotide Therapy-based Drug Revenue and Market Share, 2018-2023
4.4.1 China Based Oligonucleotide Therapy-based Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
4.5 Rest of World Based Oligonucleotide Therapy-based Drug Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antisense Oligonucleotides (ASO)
5.2.2 siRNA
5.2.3 mRNA
5.3 Market Segment by Type
5.3.1 World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023)
5.3.2 World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029)
5.3.3 World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oligonucleotide Therapy-based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Neuromuscular Diseases
6.2.2 hATTR
6.2.3 COVID-19
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023)
6.3.2 World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029)
6.3.3 World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Details
7.1.2 Sarepta Therapeutics Major Business
7.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Sarepta Therapeutics Recent Developments/Updates
7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Details
7.2.2 Ionis Pharmaceuticals Major Business
7.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
7.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Ionis Pharmaceuticals Recent Developments/Updates
7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Alnylam
7.3.1 Alnylam Details
7.3.2 Alnylam Major Business
7.3.3 Alnylam Oligonucleotide Therapy-based Drug Product and Services
7.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Alnylam Recent Developments/Updates
7.3.6 Alnylam Competitive Strengths & Weaknesses
7.4 Biogen
7.4.1 Biogen Details
7.4.2 Biogen Major Business
7.4.3 Biogen Oligonucleotide Therapy-based Drug Product and Services
7.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Biogen Recent Developments/Updates
7.4.6 Biogen Competitive Strengths & Weaknesses
7.5 Nippon Shinyaku
7.5.1 Nippon Shinyaku Details
7.5.2 Nippon Shinyaku Major Business
7.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services
7.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Nippon Shinyaku Recent Developments/Updates
7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses
7.6 Sobi
7.6.1 Sobi Details
7.6.2 Sobi Major Business
7.6.3 Sobi Oligonucleotide Therapy-based Drug Product and Services
7.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Sobi Recent Developments/Updates
7.6.6 Sobi Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Oligonucleotide Therapy-based Drug Product and Services
7.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 BioNTech
7.8.1 BioNTech Details
7.8.2 BioNTech Major Business
7.8.3 BioNTech Oligonucleotide Therapy-based Drug Product and Services
7.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 BioNTech Recent Developments/Updates
7.8.6 BioNTech Competitive Strengths & Weaknesses
7.9 Pfizer
7.9.1 Pfizer Details
7.9.2 Pfizer Major Business
7.9.3 Pfizer Oligonucleotide Therapy-based Drug Product and Services
7.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Recent Developments/Updates
7.9.6 Pfizer Competitive Strengths & Weaknesses
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Details
7.10.2 Moderna Therapeutics Major Business
7.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Moderna Therapeutics Recent Developments/Updates
7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Details
7.11.2 Jazz Pharmaceuticals Major Business
7.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
7.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
7.12 CureVac
7.12.1 CureVac Details
7.12.2 CureVac Major Business
7.12.3 CureVac Oligonucleotide Therapy-based Drug Product and Services
7.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 CureVac Recent Developments/Updates
7.12.6 CureVac Competitive Strengths & Weaknesses
7.13 Regulus Therapeutics
7.13.1 Regulus Therapeutics Details
7.13.2 Regulus Therapeutics Major Business
7.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Regulus Therapeutics Recent Developments/Updates
7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses
7.14 ProQR
7.14.1 ProQR Details
7.14.2 ProQR Major Business
7.14.3 ProQR Oligonucleotide Therapy-based Drug Product and Services
7.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 ProQR Recent Developments/Updates
7.14.6 ProQR Competitive Strengths & Weaknesses
7.15 Secarna
7.15.1 Secarna Details
7.15.2 Secarna Major Business
7.15.3 Secarna Oligonucleotide Therapy-based Drug Product and Services
7.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Secarna Recent Developments/Updates
7.15.6 Secarna Competitive Strengths & Weaknesses
7.16 MiNA Therapeutics
7.16.1 MiNA Therapeutics Details
7.16.2 MiNA Therapeutics Major Business
7.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 MiNA Therapeutics Recent Developments/Updates
7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses
7.17 Sylentis
7.17.1 Sylentis Details
7.17.2 Sylentis Major Business
7.17.3 Sylentis Oligonucleotide Therapy-based Drug Product and Services
7.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sylentis Recent Developments/Updates
7.17.6 Sylentis Competitive Strengths & Weaknesses
7.18 Arrowhead
7.18.1 Arrowhead Details
7.18.2 Arrowhead Major Business
7.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product and Services
7.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Arrowhead Recent Developments/Updates
7.18.6 Arrowhead Competitive Strengths & Weaknesses
7.19 Silence Therapeutics
7.19.1 Silence Therapeutics Details
7.19.2 Silence Therapeutics Major Business
7.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services
7.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Silence Therapeutics Recent Developments/Updates
7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
7.20 Dicerna
7.20.1 Dicerna Details
7.20.2 Dicerna Major Business
7.20.3 Dicerna Oligonucleotide Therapy-based Drug Product and Services
7.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Dicerna Recent Developments/Updates
7.20.6 Dicerna Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oligonucleotide Therapy-based Drug Industry Chain
8.2 Oligonucleotide Therapy-based Drug Upstream Analysis
8.3 Oligonucleotide Therapy-based Drug Midstream Analysis
8.4 Oligonucleotide Therapy-based Drug Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Oligonucleotide Therapy-based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Oligonucleotide Therapy-based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Oligonucleotide Therapy-based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oligonucleotide Therapy-based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Oligonucleotide Therapy-based Drug Players in 2022
Table 12. World Oligonucleotide Therapy-based Drug Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Oligonucleotide Therapy-based Drug Company Evaluation Quadrant
Table 14. Head Office of Key Oligonucleotide Therapy-based Drug Player
Table 15. Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
Table 16. Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
Table 17. Oligonucleotide Therapy-based Drug Mergers & Acquisitions Activity
Table 18. United States VS China Oligonucleotide Therapy-based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Oligonucleotide Therapy-based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 23. China Based Oligonucleotide Therapy-based Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 26. Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023) & (USD Million)
Table 31. World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029) & (USD Million)
Table 32. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023) & (USD Million)
Table 34. World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029) & (USD Million)
Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 38. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sarepta Therapeutics Recent Developments/Updates
Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Ionis Pharmaceuticals Major Business
Table 43. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
Table 44. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Ionis Pharmaceuticals Recent Developments/Updates
Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Alnylam Basic Information, Area Served and Competitors
Table 48. Alnylam Major Business
Table 49. Alnylam Oligonucleotide Therapy-based Drug Product and Services
Table 50. Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Alnylam Recent Developments/Updates
Table 52. Alnylam Competitive Strengths & Weaknesses
Table 53. Biogen Basic Information, Area Served and Competitors
Table 54. Biogen Major Business
Table 55. Biogen Oligonucleotide Therapy-based Drug Product and Services
Table 56. Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Biogen Recent Developments/Updates
Table 58. Biogen Competitive Strengths & Weaknesses
Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors
Table 60. Nippon Shinyaku Major Business
Table 61. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services
Table 62. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Nippon Shinyaku Recent Developments/Updates
Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses
Table 65. Sobi Basic Information, Area Served and Competitors
Table 66. Sobi Major Business
Table 67. Sobi Oligonucleotide Therapy-based Drug Product and Services
Table 68. Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Sobi Recent Developments/Updates
Table 70. Sobi Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Oligonucleotide Therapy-based Drug Product and Services
Table 74. Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. BioNTech Basic Information, Area Served and Competitors
Table 78. BioNTech Major Business
Table 79. BioNTech Oligonucleotide Therapy-based Drug Product and Services
Table 80. BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. BioNTech Recent Developments/Updates
Table 82. BioNTech Competitive Strengths & Weaknesses
Table 83. Pfizer Basic Information, Area Served and Competitors
Table 84. Pfizer Major Business
Table 85. Pfizer Oligonucleotide Therapy-based Drug Product and Services
Table 86. Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Recent Developments/Updates
Table 88. Pfizer Competitive Strengths & Weaknesses
Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors
Table 90. Moderna Therapeutics Major Business
Table 91. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 92. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Moderna Therapeutics Recent Developments/Updates
Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 96. Jazz Pharmaceuticals Major Business
Table 97. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
Table 98. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Jazz Pharmaceuticals Recent Developments/Updates
Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 101. CureVac Basic Information, Area Served and Competitors
Table 102. CureVac Major Business
Table 103. CureVac Oligonucleotide Therapy-based Drug Product and Services
Table 104. CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. CureVac Recent Developments/Updates
Table 106. CureVac Competitive Strengths & Weaknesses
Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors
Table 108. Regulus Therapeutics Major Business
Table 109. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 110. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Regulus Therapeutics Recent Developments/Updates
Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses
Table 113. ProQR Basic Information, Area Served and Competitors
Table 114. ProQR Major Business
Table 115. ProQR Oligonucleotide Therapy-based Drug Product and Services
Table 116. ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. ProQR Recent Developments/Updates
Table 118. ProQR Competitive Strengths & Weaknesses
Table 119. Secarna Basic Information, Area Served and Competitors
Table 120. Secarna Major Business
Table 121. Secarna Oligonucleotide Therapy-based Drug Product and Services
Table 122. Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Secarna Recent Developments/Updates
Table 124. Secarna Competitive Strengths & Weaknesses
Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors
Table 126. MiNA Therapeutics Major Business
Table 127. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 128. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. MiNA Therapeutics Recent Developments/Updates
Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses
Table 131. Sylentis Basic Information, Area Served and Competitors
Table 132. Sylentis Major Business
Table 133. Sylentis Oligonucleotide Therapy-based Drug Product and Services
Table 134. Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sylentis Recent Developments/Updates
Table 136. Sylentis Competitive Strengths & Weaknesses
Table 137. Arrowhead Basic Information, Area Served and Competitors
Table 138. Arrowhead Major Business
Table 139. Arrowhead Oligonucleotide Therapy-based Drug Product and Services
Table 140. Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Arrowhead Recent Developments/Updates
Table 142. Arrowhead Competitive Strengths & Weaknesses
Table 143. Silence Therapeutics Basic Information, Area Served and Competitors
Table 144. Silence Therapeutics Major Business
Table 145. Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 146. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Silence Therapeutics Recent Developments/Updates
Table 148. Dicerna Basic Information, Area Served and Competitors
Table 149. Dicerna Major Business
Table 150. Dicerna Oligonucleotide Therapy-based Drug Product and Services
Table 151. Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Oligonucleotide Therapy-based Drug Upstream (Raw Materials)
Table 153. Oligonucleotide Therapy-based Drug Typical Customers
LIST OF FIGURE
Figure 1. Oligonucleotide Therapy-based Drug Picture
Figure 2. World Oligonucleotide Therapy-based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Oligonucleotide Therapy-based Drug Total Market Size (2018-2029) & (USD Million)
Figure 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 13. Oligonucleotide Therapy-based Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 16. World Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 18. China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Oligonucleotide Therapy-based Drug by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug Markets in 2022
Figure 27. United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type in 2022
Figure 31. Antisense Oligonucleotides (ASO)
Figure 32. siRNA
Figure 33. mRNA
Figure 34. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)
Figure 35. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Oligonucleotide Therapy-based Drug Market Size Market Share by Application in 2022
Figure 37. Neuromuscular Diseases
Figure 38. hATTR
Figure 39. COVID-19
Figure 40. Other
Figure 41. Oligonucleotide Therapy-based Drug Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
Table 1. World Oligonucleotide Therapy-based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Oligonucleotide Therapy-based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Oligonucleotide Therapy-based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oligonucleotide Therapy-based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Oligonucleotide Therapy-based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Oligonucleotide Therapy-based Drug Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Oligonucleotide Therapy-based Drug Players in 2022
Table 12. World Oligonucleotide Therapy-based Drug Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Oligonucleotide Therapy-based Drug Company Evaluation Quadrant
Table 14. Head Office of Key Oligonucleotide Therapy-based Drug Player
Table 15. Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
Table 16. Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
Table 17. Oligonucleotide Therapy-based Drug Mergers & Acquisitions Activity
Table 18. United States VS China Oligonucleotide Therapy-based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Oligonucleotide Therapy-based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 23. China Based Oligonucleotide Therapy-based Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 26. Rest of World Based Oligonucleotide Therapy-based Drug Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Oligonucleotide Therapy-based Drug Revenue Market Share (2018-2023)
Table 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Oligonucleotide Therapy-based Drug Market Size by Type (2018-2023) & (USD Million)
Table 31. World Oligonucleotide Therapy-based Drug Market Size by Type (2024-2029) & (USD Million)
Table 32. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Oligonucleotide Therapy-based Drug Market Size by Application (2018-2023) & (USD Million)
Table 34. World Oligonucleotide Therapy-based Drug Market Size by Application (2024-2029) & (USD Million)
Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 36. Sarepta Therapeutics Major Business
Table 37. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 38. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Sarepta Therapeutics Recent Developments/Updates
Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Ionis Pharmaceuticals Major Business
Table 43. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
Table 44. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Ionis Pharmaceuticals Recent Developments/Updates
Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Alnylam Basic Information, Area Served and Competitors
Table 48. Alnylam Major Business
Table 49. Alnylam Oligonucleotide Therapy-based Drug Product and Services
Table 50. Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Alnylam Recent Developments/Updates
Table 52. Alnylam Competitive Strengths & Weaknesses
Table 53. Biogen Basic Information, Area Served and Competitors
Table 54. Biogen Major Business
Table 55. Biogen Oligonucleotide Therapy-based Drug Product and Services
Table 56. Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Biogen Recent Developments/Updates
Table 58. Biogen Competitive Strengths & Weaknesses
Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors
Table 60. Nippon Shinyaku Major Business
Table 61. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Services
Table 62. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Nippon Shinyaku Recent Developments/Updates
Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses
Table 65. Sobi Basic Information, Area Served and Competitors
Table 66. Sobi Major Business
Table 67. Sobi Oligonucleotide Therapy-based Drug Product and Services
Table 68. Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Sobi Recent Developments/Updates
Table 70. Sobi Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Area Served and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Oligonucleotide Therapy-based Drug Product and Services
Table 74. Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. BioNTech Basic Information, Area Served and Competitors
Table 78. BioNTech Major Business
Table 79. BioNTech Oligonucleotide Therapy-based Drug Product and Services
Table 80. BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. BioNTech Recent Developments/Updates
Table 82. BioNTech Competitive Strengths & Weaknesses
Table 83. Pfizer Basic Information, Area Served and Competitors
Table 84. Pfizer Major Business
Table 85. Pfizer Oligonucleotide Therapy-based Drug Product and Services
Table 86. Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Recent Developments/Updates
Table 88. Pfizer Competitive Strengths & Weaknesses
Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors
Table 90. Moderna Therapeutics Major Business
Table 91. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 92. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Moderna Therapeutics Recent Developments/Updates
Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses
Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
Table 96. Jazz Pharmaceuticals Major Business
Table 97. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Services
Table 98. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Jazz Pharmaceuticals Recent Developments/Updates
Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
Table 101. CureVac Basic Information, Area Served and Competitors
Table 102. CureVac Major Business
Table 103. CureVac Oligonucleotide Therapy-based Drug Product and Services
Table 104. CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. CureVac Recent Developments/Updates
Table 106. CureVac Competitive Strengths & Weaknesses
Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors
Table 108. Regulus Therapeutics Major Business
Table 109. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 110. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Regulus Therapeutics Recent Developments/Updates
Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses
Table 113. ProQR Basic Information, Area Served and Competitors
Table 114. ProQR Major Business
Table 115. ProQR Oligonucleotide Therapy-based Drug Product and Services
Table 116. ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. ProQR Recent Developments/Updates
Table 118. ProQR Competitive Strengths & Weaknesses
Table 119. Secarna Basic Information, Area Served and Competitors
Table 120. Secarna Major Business
Table 121. Secarna Oligonucleotide Therapy-based Drug Product and Services
Table 122. Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Secarna Recent Developments/Updates
Table 124. Secarna Competitive Strengths & Weaknesses
Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors
Table 126. MiNA Therapeutics Major Business
Table 127. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 128. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. MiNA Therapeutics Recent Developments/Updates
Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses
Table 131. Sylentis Basic Information, Area Served and Competitors
Table 132. Sylentis Major Business
Table 133. Sylentis Oligonucleotide Therapy-based Drug Product and Services
Table 134. Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sylentis Recent Developments/Updates
Table 136. Sylentis Competitive Strengths & Weaknesses
Table 137. Arrowhead Basic Information, Area Served and Competitors
Table 138. Arrowhead Major Business
Table 139. Arrowhead Oligonucleotide Therapy-based Drug Product and Services
Table 140. Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Arrowhead Recent Developments/Updates
Table 142. Arrowhead Competitive Strengths & Weaknesses
Table 143. Silence Therapeutics Basic Information, Area Served and Competitors
Table 144. Silence Therapeutics Major Business
Table 145. Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Services
Table 146. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Silence Therapeutics Recent Developments/Updates
Table 148. Dicerna Basic Information, Area Served and Competitors
Table 149. Dicerna Major Business
Table 150. Dicerna Oligonucleotide Therapy-based Drug Product and Services
Table 151. Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Oligonucleotide Therapy-based Drug Upstream (Raw Materials)
Table 153. Oligonucleotide Therapy-based Drug Typical Customers
LIST OF FIGURE
Figure 1. Oligonucleotide Therapy-based Drug Picture
Figure 2. World Oligonucleotide Therapy-based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Oligonucleotide Therapy-based Drug Total Market Size (2018-2029) & (USD Million)
Figure 4. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Oligonucleotide Therapy-based Drug Revenue (2018-2029) & (USD Million)
Figure 13. Oligonucleotide Therapy-based Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 16. World Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 18. China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Oligonucleotide Therapy-based Drug by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oligonucleotide Therapy-based Drug Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oligonucleotide Therapy-based Drug Markets in 2022
Figure 27. United States VS China: Oligonucleotide Therapy-based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Oligonucleotide Therapy-based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Oligonucleotide Therapy-based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type in 2022
Figure 31. Antisense Oligonucleotides (ASO)
Figure 32. siRNA
Figure 33. mRNA
Figure 34. World Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2018-2029)
Figure 35. World Oligonucleotide Therapy-based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Oligonucleotide Therapy-based Drug Market Size Market Share by Application in 2022
Figure 37. Neuromuscular Diseases
Figure 38. hATTR
Figure 39. COVID-19
Figure 40. Other
Figure 41. Oligonucleotide Therapy-based Drug Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
